Colorectal cancer recurrence gene expression signature

Patent metadata

Field	Value
Publication number	US-11035006-B2
Application number	US-201414907372-A
Country	US
Kind code	B2
Filing date	Jul 30, 2014
Priority date	Jul 30, 2013
Publication date	Jun 15, 2021
Grant date	Jun 15, 2021

Abstract

Disclosed are gene signatures that may be used to predict the recurrence of colorectal cancer in a human patient. These signatures can be used to determine when to treat a patient with post-operative adjuvant chemotherapy, i.e., when a high risk of colorectal cancer recurrence is predicted.

First claim

What is claimed is:

1. A method for treating a human patient with Dukes B colorectal cancer with adjuvant chemotherapy the method comprising:
(a) assaying colorectal cells from the human patient for the expression level of ten (10) or more genes associated with SEQ ID NOS: 7, 13, 18, 19, 30, 38, 43, 45, 52, 59, 67, 69, 76, 94, 95, 97, 98, 100, 101, 103, 104, 106, 122, 123, 127, 134, 135, 139, 142, 148, and 311-404, or their corresponding expression products, and ten (10) or more genes associated with SEQ ID NOS: 160, 173, 177, 190, 192, 213, 223, 230, 241, 248, 276, 280, 289, 295, 310, and 405-508, or their corresponding expression products, and using normalized values of the expression levels to calculate a colorectal cancer (CRC) score;
(b) assaying colorectal cells from the human patient for the expression levels of ten (10) or more genes associated with SEQ ID NOS: 1-149, or their corresponding expression products, and ten (10) or more genes associated with SEQ ID NOS: 150-310, or their corresponding expression products, and using normalized values of the expression levels to calculate an Epithelial to Mesenchymal Transition (EMT) score; and
(c) calculating the difference between the CRC score and the EMT score to arrive at a Recurrence Signature Score that determines that the patient with Dukes B colorectal cancer has a high risk of recurrence of colorectal cancer and would benefit from adjuvant chemotherapy; and
d); and
treating the patient from step d) above with adjuvant chemotherapy.

2. The method of claim 1 , further comprising displaying or outputting to a user, user interface device, computer readable storage medium, or local or remote computer system the calculated risk of colorectal cancer recurrence.

3. The method of claim 1 , wherein the chemotherapy comprises a 5-fluorouracil (5-FU) therapy.

4. The method of claim 1 , wherein increased expression of the genes associated with SEQ ID NOS: 7, 13, 18, 19, 30, 38, 43, 45, 52, 59, 67, 69, 76, 94, 95, 97, 98, 100, 101, 103, 104, 106, 122, 123, 127, 134, 135, 139, 142, 148, and 311-404, or their corresponding expression products, increases the CRC score; and wherein increased expression of the genes associated with SEQ ID NOS: 160, 173, 177, 190, 192, 213, 223, 230, 241, 248, 276, 280, 289, 295, 310, and 405-508, or their corresponding products, decreases the CRC score.

5. The method of claim 1 , wherein increased expression of the genes associated with SEQ ID NOS: 1-149, or their corresponding expression products, increases the EMT score; and wherein increased expression of the genes associated with SEQ ID NOS: 150-310, or their corresponding products, decreases the EMT score.

6. The method of claim 1 , wherein the expression levels are normalized by quantile normalization.

7. The method of claim 1 , wherein the normalized expression values of the expression levels for each assayed gene are given equal weight in calculating the CRC score.

8. The method of claim 1 , wherein the normalized expression values of the expression levels for each assayed gene are given equal weight in calculating the EMT score.

9. A method for treating a human patient with of Dukes B colorectal cancer with adjuvant chemotherapy the method comprising:
(a) assaying colorectal cells from the human patient for normalized expression values of ten (10) or more genes associated with SEQ ID NOS: 1-149, ten (10) or more genes associated with SEQ ID NOS: 150-310, ten (10) or more genes associated with SEQ ID NOS: 7, 13, 18, 19, 30, 38, 43, 45, 52, 59, 67, 69, 76, 94, 95, 97, 98, 100, 101, 103, 104, 106, 122, 123, 127, 134, 135, 139, 142, 148, and 311-404, and ten (10) or more genes associated with SEQ ID NOS: 160, 173, 177, 190, 192, 213, 223, 230, 241, 248, 276, 280, 289, 295, 310, and 405-508;
(b) inputting the normalized expression values into a computer programmed to execute an algorithm to convert the normalized expression values to a Recurrence Signature Score indicative that the subject would benefit from adjuvant chemotherapy, wherein the algorithm gives reduced weight to the normalized expression values for genes that are listed more than once in step a); and further wherein the algorithm converts the normalized expression values for the genes associated with SEQ ID NOS: 7, 13, 18, 19, 30, 38, 43, 45, 52, 59, 67, 69, 76, 94, 95, 97, 98, 100, 101, 103, 104, 106, 122, 123, 127, 134, 135, 139, 142, 148, and 311-404 and the genes associated with SEQ ID NOS: 160, 173, 177, 190, 192, 213, 223, 230, 241, 248, 276, 280, 289, 295, 310, and 405-508 to a colorectal cancer (CRC) score, wherein the algorithm converts the normalized expression values for the genes associated with SEQ ID NOS: 1-310 to an Epithelial to Mesenchymal Transition (EMT) score, wherein the Recurrence Signature Score is determined by calculating the difference between the CRC score and the EMT score; and
c)
treating the human patient with Dukes B colorectal cancer and a high risk of colorectal cancer recurrence by providing adjuvant chemotherapy.

10. The method of claim 9 , wherein increased expression of the genes associated with SEQ ID NOS: 7, 13, 18, 19, 30, 38, 43, 45, 52, 59, 67, 69, 76, 94, 95, 97, 98, 100, 101, 103, 104, 106, 122, 123, 127, 134, 135, 139, 142, 148, and 311-404, or their corresponding expression products, increases the CRC score; and wherein increased expression of the genes associated with SEQ ID NOS: 160, 173, 177, 190, 192, 213, 223, 230, 241, 248, 276, 280, 289, 295, 310, and 405-508, or their corresponding products, decreases the CRC score.

11. The method of claim 9 , wherein increased expression of the genes associated with SEQ ID NOS: 1-149, or their corresponding expression products, increases the EMT score; and wherein increased expression of SEQ ID NOS: 150-310, or their corresponding products, decreases the EMT score.

12. The method of claim 9 , wherein the chemotherapy comprises a 5-fluorouracil (5-FU) therapy.

13. The method of claim 9 , wherein the expression levels are normalized by quantile normalization.

14. The method of claim 9 , wherein the normalized expression values of the expression levels for each assayed gene are given equal weight in calculating the CRC score.

15. The method of claim 9 , wherein the normalized expression values of the expression levels for each assayed gene are given equal weight in calculating the EMT score.

16. A method for treating a human patient with Dukes C colorectal cancer, wherein the subject is treated with surgery but is not treated with post-operative adjuvant chemotherapy within 6 months of surgery, the method comprising:
(a) assaying colorectal cells from the human patient for the expression level of ten (10) or more genes associated with SEQ ID NOS: 7, 13, 18, 19, 30, 38, 43, 45, 52, 59, 67, 69, 76, 94, 95, 97, 98, 100, 101, 103, 104, 106, 122, 123, 127, 134, 135, 139, 142, 148, and 311-404, or their corresponding expression products, and ten (10) or more genes associated with SEQ ID NOS: 160, 173, 177, 190, 192, 213, 223, 230, 241, 248, 276, 280, 289, 295, 310, and 405-508, or their corresponding expression products, and using normalized values of the expression levels to calculate a colorectal cancer (CRC) score;
(b) assaying colorectal cells from the human patient for the expression levels of ten (10) or more genes associated with SEQ ID NOS: 1-149, or their corresponding expression products, and ten (10) or more genes associated with SEQ ID NOS: 150-310, or their corresponding expression products, and using normalized values of the expression levels to calculate an Epithelial to Mesenchymal Transition (EMT) score; and
(c) ca

Assignees

• H Lee Moffitt Cancer Ct & Res
• Gibbs Cancer Center
• Gibbs Cancer Center & Res Institute

Inventors

• Schell Michael
• Yeatman Timothy

Classifications

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title